A combination treatment involving lipofermata and a CTLA4 antibody in TC-1 and LLC tumor-bearing mice demonstrated a synergistic tumor-suppressive effect compared to treatment with either agent alone. The gene discussed is CTLA4; the disease is neoplasm.